Drugs / TBO-309
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06813651 | Oct 2025 → Dec 2026 expected | ischemic stroke, occlusion precerebral artery | ThromBio Pty. Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05363397 | Sep 2023 → Feb 2026 overdue | ischemic stroke | The Florey Institute of Neuroscience and Mental Health | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBO-309 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05363397 ↗ |
| Action | Inhibit | “PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation” NCT05363397 ↗ |
| Route | Intravenous | “The allocated dose of TBO-309 will be given intravenously as follows:” NCT05363397 ↗ |